Cargando…

What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?

The U.S. Food and Drug Administration (FDA) approved inhaled insulin (INH) under the trade name Exubera on January 27, 2006, for use in adult patients with type 1 and type 2 diabetes. Exubera is an inhalable, powdered form of insulin delivered by a device developed by Nektar Therapeutics. Earlier in...

Descripción completa

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437679/ https://www.ncbi.nlm.nih.gov/pubmed/16515377 http://dx.doi.org/10.18553/jmcp.2006.12.2.169

Ejemplares similares

Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
por: Hwang, Mina, et al.
Publicado: (2021)

PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
por: Jarrar, Mohammed H, et al.
Publicado: (2007)

Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
por: Schwartz, Ann V.
Publicado: (2006)

TZDs and Bone: A Review of the Recent Clinical Evidence
por: Schwartz, Ann V.
Publicado: (2008)

Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
por: Cho, Eun-Hee
Publicado: (2022)

Type 2 Diabetes: Uses of thiazolidinediones and insulin
por: T. Bloomgarden, Zachary
Publicado: (2011)

HEDIS, Beta-Blockers, and What More Can Be Done to Improve Secondary Prevention in ACS
por: Curtiss, Frederic R.
Publicado: (2008)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation
por: Lee, Ji-Yeon, et al.
Publicado: (2018)

United States, The Last Venue for Direct-to-Customer Advertising, Props Up the Erectile Dysfunction Market
por: Curtiss, Frederic R.
Publicado: (2005)

What Should Be Done About Bias and Misconduct in Clinical Trials?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

ADD or ADHD or What Exactly?--GIGO Part II and Other Lessons in Research with Administrative Claims
por: Curtiss, Frederic R., et al.
Publicado: (2007)

It Depends on What Mean Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data
por: Fairman, Kathleen A., et al.
Publicado: (2010)

COPD - Whose Burden, How Large, and What to Do About It?
por: Curtiss, Frederic R.
Publicado: (2005)

Why e-Prescribe and the Future of Transforming Data Into Information
por: Curtiss, Frederic R.
Publicado: (2005)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

Inhale the future, exhale the past
por: Kumar, Ashish
Publicado: (2017)

Commentary: Why Was Inhaled Insulin a Failure in the Market?
por: Oleck, Jacob, et al.
Publicado: (2016)

Effects of Combination of Thiazolidinediones with Melatonin in Dexamethasone-induced Insulin Resistance in Mice
por: Ghaisas, M. M., et al.
Publicado: (2011)

Evidence-Based Medicine: Are SSRIs More Effective Than Placebo and What Length of Therapy is Enough?
por: Curtiss, Frederic R.
Publicado: (2005)

Step-Therapy Edits for PPIs and COX-2 Drugs - What We Do and Do Not Know
por: Curtiss, Frederic R.
Publicado: (2004)

PandT Committees - Black Boxes Versus AMCP Format, and What Is the True Cost and Value of Pimecrolimus
por: Curtiss, Frederic R.
Publicado: (2005)

Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
por: Chang, Eugene, et al.
Publicado: (2013)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

COVID-19’s Impacts on Housing Markets: Introduction
por: Schwartz, Amy Ellen, et al.
Publicado: (2023)

Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)

Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011)

Brain PPARγ Promotes Obesity and is Required for the Insulin–Sensitizing Effect of Thiazolidinediones
por: Lu, Min, et al.
Publicado: (2011)

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015)

A Thiazolidinedione Improves In Vivo Insulin Action on Skeletal Muscle Glycogen Synthase in Insulin-Resistant Monkeys
por: Ortmeyer, Heidi K., et al.
Publicado: (2000)

Timely insulin use: Need for social marketing
por: Kalra, Sanjay, et al.
Publicado: (2016)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Thiazolidinediones are partially effective bitter blockers
por: Nguyen, Ha, et al.
Publicado: (2023)

Internet marketing in the medical industry; challenges and future
por: Lee, Bu-Kyu
Publicado: (2015)

Measuring Value in the Treatment of Symptoms of Allergic Rhinitis With Nasal Steroids
por: Curtiss, Frederic R.
Publicado: (2006)

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006)

Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)

Rhythm Versus Safety in Amiodarone Therapy
por: Curtiss, Frederic R.
Publicado: (2006)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_q1c0gde69032iprj2eova7gl74